对缺血性核心划分的最佳明显扩散系数值进行修订
Clara Cohen1,2, Clément Debacker2, Alice Le Berre2,3
1Department of Neuroradiology, University Hospital of Orleans, France.
Neurology
|December 26, 2025
概括
这项研究重新评估了在接受内血管治疗 (EVT) 的患者中缺血性中风核心划分的明显扩散系数 (ADC) 值. 优化的ADC值与标准值相似,对核心体积测量的影响最小.
科学领域:
- 神经成像是一种神经成像.
- 脑卒中研究 脑卒中研究
- 医学图像分析 医学图像分析
背景情况:
- 缺血核心划分的标准显微扩散系数 (ADC) 值是使用较旧的再通道化评估时间表和没有瘤纠正而建立的.
- 之前的方法可能会高估缺血核心,原因是延迟了再通道评估,并且在后续成像中缺乏血管性水纠正.
研究的目的:
- 重新评估最佳的ADC值,以界定缺血核心在内血管治疗 (EVT) 后早期再通道化的患者.
- 评估纠正 (EC) 和早期随访成像 (≈24小时) 对ADC值确定的影响.
主要方法:
- 对接受EVT的患者进行回顾性分析,在90分钟内成功进行再通道化,并进行了24小时的随访MRI.
- 在扩散权重成像 (DWI) 上手动划分基线缺血病变和最终心脏病发作 (Infarct24h).
- 应用非线性同注册以纠正 (EC) 和接受器运行特征分析,以确定最佳的ADC值 (OptADC).
主要成果:
- 优化的ADC值 (OptADC) 与水纠正为612 × 10-6 mm2 / s,曲线下的面积为0.704.
- 个体OptADC的中位数为621.5 × 10-6 mm2 / s.
- 与参考值相比,优化值导致基线核心体积略小,观察到的临床差异最小.
结论:
- 使用严格的方法 (早期再通道,24小时随访MRI,EC) 确定的优化ADC值与参考值相当.
- 方法上的改进,包括的纠正,对于在急性缺血性中风中对ADC核心划分的未来研究至关重要.
相关概念视频
Assessment of Diffusion and Perfusion
1.5K
Understanding and evaluating diffusion and perfusion is critical in assessing a patient's respiratory and circulatory health. These processes play key roles in maintaining the body's internal environment, ensuring that tissues receive adequate oxygen while waste products are efficiently removed.
The Role of Diffusion in Respiration
Diffusion is the process by which molecules move from an area of higher concentration to an area of lower concentration. In the respiratory system, this...
The Role of Diffusion in Respiration
Diffusion is the process by which molecules move from an area of higher concentration to an area of lower concentration. In the respiratory system, this...
1.5K
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
362
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
362


